肿瘤细胞治疗研究
MODALITY HUB
FOR TREATMENT
按「中国试验优先 → 正在招募 → 更新更近」排序。信息来自 ClinicalTrials.gov 与 CDE 公开登记。能否入组、费用与可及性，以登记原文和主治医生判断为准。
FOR RESEARCH
Erratum to "CircRNA-based CD19-targeted CAR-NK therapy for B-cell acute lymphoblastic leukemia using a Coccidioides immitis-derived group II intron pl
Pluripotent stem cell-derived CAR-NK progenitor therapy targets minimal residual disease and prevents relapse in leukemia models.
降低化疗后的复发率仍是提高肿瘤治疗疗效的一大挑战。
Donor-derived CD19-targeted CAR-NK cells induce complete remission in a child with relapsed B-ALL after failure of blinatumomab and autologous CD19-ta
复发仍是儿童 B 细胞急性淋巴细胞白血病（B-ALL）治疗失败和死亡的主要原因。
CircRNA-based CD19-targeted CAR-NK therapy for B-cell acute lymphoblastic Leukemia using a Coccidioides immitis-derived group II intron platform.
这些结果支持基于circRNA的CAR-NK疗法作为提高癌症免疫治疗安全性和有效性的一种有效方法的潜力。
Combination of targeted pharmacotherapy and immunotherapy with anti-CD19 CAR NK cells in acute lymphoblastic leukemia.
这些数据表明 aCD19 CAR NK 细胞作为 BCP-ALL 联合治疗组成部分的潜力，应在临床试验中进一步评估。
Tumor-priming CD8(+) natural killer T-like cells as an efficient novel cell therapy for relapsed/refractory multiple myeloma.
TPNC 是一种通过肿瘤驱动的致敏产生的新型细胞毒性淋巴细胞产品。
iPSC-derived NK cells with site-specific integration of CAR19 and IL24 at the multi-copy rDNA locus enhanced antitumor activity and proliferation.
利用诱导多能干细胞（iPSC）制备嵌合抗原受体修饰的自然杀伤（CAR-NK）细胞，已成为生产现货型通用免疫疗法的范式之一。
CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia.
CD19/CD20双靶向CAR-NK细胞的创建解决了ALL中因抗原异质性导致的肿瘤逃逸风险，提供了高效、安全的“现货型”细胞产品。这些细胞在ALL中靶向CD20和/或CD19抗原方面显示出疗效，为其在ALL治疗中的应用奠定了实验基础。
Preclinical Evaluation of CRISPR-Edited CAR-NK-92 Cells for Off-the-Shelf Treatment of AML and B-ALL.
这些结果表明，CD19-CAR和CD276-CAR-NK-92细胞系的细胞毒性表现适合用于白血病杀伤，使其成为有前景的现货型治疗候选药物。
Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies.
我们的研究为生成纯度高且活性强的同种异体CAR NK细胞提供了重要见解，从而进一步推动了利用CAR NK细胞进行过继性细胞免疫治疗人类恶性肿瘤的进展。
MEMBER ACCOUNT
登录成功会直接打开下一页。
